Preclinical studies with this compound in APP/PS1 mice indicated that one-month oral administration of GV-971 effectively reconditioned the alterations in gut microbiota, leading to a decrease in infiltrated Th1-cells, neuroinflammation, and AD-like pathology in the brain [174]. Here, APP is linked to Alzheimer disease.